Dublin, May 05, 2021 (GLOBE NEWSWIRE) – The report “Needle-Free Diabetes Management Market Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021-2029” has been added ResearchAndMarkets.com Offer.
This report, titled “Needle-Free Diabetes Management,” examines different types of devices such as treatment devices, diagnostic devices, and artificial pancreas, each of which is divided. According to the International Diabetes Federation, one in 11 adults will have diabetes in 2015 and one in ten adults is expected to have diabetes by 2040. The data suggest that one person dies of diabetes every 6 seconds in 2015. Therefore, diabetes management is one of the most important aspects to prevent the life-threatening effects of this disease. The ongoing research and development activities in the field of diagnosis and treatment of diabetes are expected to change the aspect of the market in the coming years.
For the purposes of this study, the worldwide Needle-Free Diabetes Management Market is divided into Treatment Devices, Diagnostic Devices, and Artificial Pancreas on the basis of device type. Treatment devices include insulin pens, pumps and patches, inhalers and jet injectors. Diagnostic devices are further subdivided into CGM devices (Continuous Glucose Monitoring) and FGM systems (Flash Glucose Monitoring). Market size estimates and forecasts for these segments for the period 2019 to 2029 are given in USD Mn along with the respective compound annual growth rates (CAGRs) for the period 2021 to 2029, taking 2020 as the base year.
The Needle-Free Diabetes Management market has been geographically segmented into key regions such as North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Each geographic market is further split to provide market revenue for select countries such as the US, Canada, UK, Germany, China, Japan, Brazil and the GCC countries. The market size and forecast for these segments in the years 2019 to 2029 as well as their CAGR for the period 2021 to 2029 are contained in this report.
The major players in the Needle-Free Diabetes Management market are based on various characteristics such as business description, financial health and budget allocation, product portfolio, and reporting. The key players described in this report are Zogenix, Inc., 3M, Antares Pharma Inc., Glide Pharmaceutical Technologies Ltd., Injex Pharma AG, Pharmajet, Inc., Bioject Medical Technologies, Inc., Medtronic, Inc., Johnson & Johnson, Inc., Pancreum LLC, Tandem Diabetes Care, Inc., JDRF and Akra Dermojet.
Based on the Device Type, the Worldwide Needle-Free Diabetes Management Market is segmented as follows:
- Treatment devices
- Insulin jet injector
- Insulin pen
- Insulin inhaler
- Insulin patch & pump
- Diagnostic equipment
- CGM system (Continuous Glucose Monitoring)
- Flash Glucose Monitoring (FGM) System
- Artificial pancreas
In the base year 2020, insulin patches and pumps were observed to be the fastest growing segment in the treatment device segment due to their high efficiency, patient comfort and increasing public awareness of the new needle-free treatment devices. Insulin pens and jet injectors together accounted for the largest market share of around 51% of the total needle-free diabetes treatment market, as they are one of the first treatment solutions available on the market, have high market penetration to date and a high level of public awareness related to the products . According to CGM, the flash glucose monitoring system is considered to be the most innovative device for diabetes monitoring.
Abbott Laboratories launched the first flash glucose monitoring system called FreeStyle Libre, which received the European CE Mark in February 2016. Available in several European countries, the FreeStyle Libre flash glucose monitoring system is designed to change the way people with diabetes measure their glucose and ultimately help them achieve better health outcomes. The system reads the glucose level through a sensor that is worn on the back of the upper arm for up to 14 days, eliminating the need for routine finger pricks. In addition, no calibration of the fingerprint is seen as a critical differentiator compared to current continuous glucose monitoring systems.
An artificial pancreas system includes a continuous glucose monitor (CGM) and a continuous subcutaneous insulin infusion pump, both of which are commercially available today, as well as a controller that connects the monitor and the pump and runs a sophisticated algorithm to deliver the appropriate amount of determine insulin for delivery and when to deliver based on real-time glucose readings. Such systems are expected to mimic the functions of a healthy pancreas by combining continuous glucose monitoring, remote-controlled insulin pumps, and artificial intelligence to automatically maintain healthy blood sugar levels.
For the purposes of this study, the global Needle-Free Diabetes Management Market is segmented into the following categories:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
In the base year 2020, North America was observed as the largest and most potential regional market for needle-free diabetes management. North America forms the regional markets of the USA and Canada. The proliferation of diabetes is the main driver of the growth of the North American market for needle-free diabetes management. The developed health infrastructure, high public awareness of diabetes management, and increasing research and development activities related to diabetes management are the key drivers for the growth of the North American needle-free diabetes management market.
According to reports from the International Diabetes Federation (IDF), around 382 million people were diagnosed with diabetes worldwide in 2013, and that number is projected to rise to 592 million by 2035. Asia Pacific is expected to be the fastest growing regional needle-free diabetes management market through 2029. Over the next six years, Asia Pacific market growth is expected to be focused on Japan, South Korea, China and India. Numerous factors such as the development of the economic landscape and industrialization, the increase in disposable income, the growing public awareness of diabetes management, and the increasing rate of diagnosis that provides favorable environments for glucose monitoring devices are the main factors driving the growth of the Asia-Pacific market are likely to support.
Main topics covered:
Chapter 1 Foreword
Chapter 2 Summary
2.1 Global Needle-Free Diabetes Management Market, By Device Type, 2020 v / s 2029 (Value%)
2.2 Global Needle-Free Diabetes Management Market by Geography, 2020 (Value%)
Chapter 3 Global Needle-Free Diabetes Management Market Review
3.1 Overview
3.2 Market drivers
3.2.1 Increase in the prevalence of diabetes due to increasing obesity and sedentary lifestyle in people
3.2.2 Growing development and success of continuous glucose monitors
3.3 Market Restrictions
3.3.1 Creating a Fast-Acting Insulin and Glucagon Formula
3.3.2 Regulatory hurdles and cost restrictions
3.4 Market Opportunities
3.4.1 Development of next generation glucose sensors
3.4.2 Intensive investment in R&D efforts
3.5 Attractive investment offer
3.6 Assessment of market competition: needle-free diabetes management by major players
3.6.1 Needle-Free Diabetes Management Market, Key Players Analysis by Treatment Devices
3.6.2 Needle-Free Diabetes Management Market, Key Players Analysis by Diagnostic Devices
Chapter 4 Global Needle-Free Diabetes Management Market Analysis, By Device Type
4.1 Overview
4.2 Treatment devices
4.2.1 Insulin jet injector
4.2.2 Insulin pen
4.2.3 Insulin inhaler
4.2.4 Insulin Patch & Pump
4.3 Diagnostic devices
4.3.1 Continuous Glucose Monitoring System (CGM)
4.3.2 Flash Glucose Monitoring (FGM) System
4.4 Devices and systems for artificial pancreas
Chapter 5 Global Diabetes Management Needle-Free Transplant Market By Geography
5.1 Foreword
5.2 North America
5.2.1 US
5.2.2 Canada
5.3 Europe
5.3.1 UK
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 Japan
5.4.2 China
5.4.3 Rest of Asia Pacific
5.5 Latin America
5.5.1 Brazil
5.5.2 Mexico
5.5.3 Rest of Latin America
5.6 Middle East and Africa
Chapter 6 Company Profiles
6.1 Zogenix, Inc.
6.1.1 Zogenix, Inc .: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
6.2 3M
6.2.1 3M: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
6.3 Antares Pharma Inc.
6.3.1 Antares Pharma Inc .: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
6.4 Glide Pharmaceutical Technologies Ltd.
6.4.1 Glide Pharmaceutical Technologies Ltd .: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
6.5 Injex Pharma AG
6.5.1 Injex Pharma AG: company snapshot (business description; financial health and budget allocation; product position / portfolio; reporting)
6.6 Pharmajet, Inc.
6.6.1 Pharmajet, Inc .: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
6.7 Bioject Medical Technologies, Inc.
6.7.1 Bioject Medical Technologies, Inc .: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
6.8 Medtronic, Inc.
6.8.1 Medtronic, Inc .: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
6.9 Johnson & Johnson, Inc.
6.9.1 Johnson & Johnson, Inc .: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
6.10 Pancreum LLC
6.10.1 Pancreum LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
6.11 Tandem Diabetes Care, Inc.
6.11.1 Tandem Diabetes Care, Inc .: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
6.12 JDRF
6.12.1 JDRF: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
6.13 acres of dermojet
6.13.1 Akra Dermojet: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position / Portfolio; Reporting)
Please visit https://www.researchandmarkets.com/r/fwuz2j for more information on this report
